Search the Newsreel

OptimizeRx Corp (OPRX) Institutional Confidence

OptimizeRx Corp (OPRX) has an institutional shareholding score of 7.00, ranking 139th out of 485 in the Software & IT Services industry. The institutional shareholding proportion recently increased by 8.32% quarter-over-quarter to 82.46%. The largest institutional shareholder is Bill Nygren | OAKMX, holding 1.14M …

OPRX|OptimizeRx Corp|Price:6.240|Chg%:+0.030

OptimizeRx Corp (OPRX) shows strong fundamentals and high growth potential, with its valuation deemed fairly valued within the Software & IT Services industry. Analysts have rated it a "Buy" with a target price of $12.40. While the stock has seen strong market performance, technical …

OptimizeRx appoints Sarah Bast as chief marketing officer By Investing.com

OptimizeRx Corp. (NASDAQ:OPRX) announced the appointment of Sarah Bast as Chief Marketing Officer. Bast brings over 20 years of pharmaceutical marketing experience, having previously served as Executive Vice President at Publicis Health Media and guided marketing strategy for major life sciences companies. In her …

OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Sarah Bast …

Sarah Bast Brings More Than Two Decades of Pharma Marketing to OptimizeRx

OptimizeRx (Nasdaq: OPRX) has appointed Sarah Bast as its new Chief Marketing Officer, effective July 23, 2026. Bast brings over two decades of experience in pharmaceutical marketing, specializing in point of care media strategy, analytics, and optimization. In her new role, she will lead …

Royce & Associates (OPRX) discloses 1.09M-share passive stake in OptimizeRx

Royce & Associates, LP has disclosed a passive stake of 1,089,398 shares in OptimizeRx Corp (OPRX), representing 5.81% of the company's common stock as of June 30, 2026. Royce & Associates, an indirect majority-owned subsidiary of Franklin Resources, Inc., holds this position for its …

OptimizeRx Corp. (NASDAQ:OPRX) Sees Significant Decline in Short Interest

OptimizeRx Corp. (NASDAQ:OPRX) experienced a significant 39% decrease in short interest in June, bringing the total short interest to 1,129,328 shares. The company's stock rose 2.0% to $6.78, and its recent earnings exceeded expectations with an EPS of $0.14 against a $0.01 consensus. Analysts …

OPRX Forecast — Price Target — Prediction for 2027

OptimizeRx Corporation (OPRX) Jumps 4.5% as Shares Reclaim Key Support - Algorithmic Stock Picks

Some OptimizeRx Corporation (NASDAQ:OPRX) Analysts Just Made A Major Cut To Next Year's Estimates

Need To Know: Analysts Just Made A Substantial Cut To Their OptimizeRx Corporation (NASDAQ:OPRX) Estimates

OptimizeRx Corporation (OPRX) Releases Q1 2026 Earnings: Revenue Down but Beats; EPS Miss

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline

OptimizeRx will post quarterly results before a May 12 investor call

How The OptimizeRx (OPRX) Narrative Is Shifting As Revenue Caution Meets Profit Optimism

OPRX Cuts Revenue Outlook: Temporary Reset or Structural Concern?

OptimizeRx: Q4 Earnings Report Indicates Caution For 2026 (NASDAQ:OPRX)

OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?